Gain Therapeutics Inc (GANX) Stock Analysis

Gain Therapeutics Inc (GANX) is a publicly traded company in the HEALTHCARE sector. It trades at $1.83, carries a market capitalization of $83.17M. This page summarizes the public market data, fundamentals, and frequently asked questions for GANX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Gain Therapeutics Inc currently has a Bullish sentiment score of 0.25.

About Gain Therapeutics Inc

Gain Therapeutics Inc. is a biotechnology firm headquartered in Bethesda, Maryland, dedicated to developing innovative therapies aimed at combating diseases related to protein misfolding. Utilizing its proprietary drug discovery platform, the company is advancing a robust pipeline of candidate therapies targeting neurodegenerative and other serious disorders. With a strong emphasis on addressing significant unmet medical needs, Gain Therapeutics is strategically positioned to make impactful c...

GNG Research Analysis

GNG Research scores Gain Therapeutics Inc (GANX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GANX.

Frequently Asked Questions

Does GANX pay dividends?

Gain Therapeutics Inc (GANX) does not currently pay a regular dividend.

What is GANX's market cap?

Gain Therapeutics Inc (GANX) has a market capitalization of $83.17M with a current stock price of $1.83.